AGIO
Live chart
What they do
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
For information only · Important disclosures
Grades vs sector
No sector grades for AGIO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.63 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-4.02 vs trailing $-7.01. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 4/9 · last two fiscal years
Altman Z-score 14.6 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $54.0M | $-412.8M | $-377.3M |
| 2024 | $36.5M | $673.7M | $-391.5M |
| 2023 | $26.8M | $-352.1M | $-297.1M |
| 2022 | $14.2M | $-231.8M | $-314.4M |
| 2021 | $0 | $1.6B | $-413.1M |
| 2020 | $0 | $-327.4M | $-304.9M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +56.0%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | -1.66 | -1.69 | -1.5% |
| 2026-04-29 | -1.79 | -1.69 | +5.7% |
| 2026-02-12 | -1.94 | -1.85 | +4.9% |
| 2025-10-30 | -1.90 | -1.78 | +6.5% |
| 2025-07-31 | -1.75 | -1.93 | -10.0% |
| 2025-05-01 | -1.76 | -1.55 | +11.9% |
| 2025-02-13 | -1.63 | -1.74 | -6.8% |
| 2024-10-31 | 7.91 | -1.47 | -118.5% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $44.7M | +259.3% |
| 2026-03-31 | $20.7M | – |
| 2025-12-31 | $20.0M | – |
| 2025-09-30 | $12.9M | – |
| 2025-06-30 | $12.5M | – |
Analyst actions
PT $37
PT $50
PT $34
PT $52
PT $39
PT $55
Insider trades
$914.4K
Stats refreshed 2026-10-21 18:28:53 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026